Lung Cancer: Clinical Research Data vs. Real World Data. Comparable?

In a conversation with a colleague, I was telling him that it would be nice to have more real world practice data on their treatment for stage 4 lung cancer.

It would be interesting to see if results from real world practice is similar (or not) to those reported in clinical trials, which are conducted and tightly monitored for treatment effectiveness and patient safety.

Just to be clear, the main reason for clinical research, is to reflect the treatment effectiveness and safety in target population (eg. lung cancer patients) in an unbiased manner.

In phase 3 clinical trials, the new study drug is always compared to ‘standard of care’ treatment. Patients who participate in clinical trial are randomised into either new study drug or ‘standard of care’ treatment but patients themselves and the doctors won’t know which treatment they are getting to prevent bias during assessment.

In two large phase 3 clinical research trials, LUX-Lung 3 and in LUX-Lung 6, the median/ average overall survival for stage 4 lung cancer patients who were on afatinib (2nd generation EGFR-TKI) was 23.1 – 28.2 months.

Real world practice data is data collected from large centre(s) and published after the medication had been approved for commercial use by government regulatory authorities such as FDA, European Medicines Agency (EMA) and in Malaysia, the National Pharmaceutical Regulatory Agency (NPRA).

Screen Shot 2018-04-14 at 1.47.49 AM

Few real world practice data is available. An example of real world practice data with the same medication (afatinib) is from National Cancer Centre Singapore, 2017 which showed median/ average survival duration of 29.6 months (95% CI: 24.0 to 46.4 months) for 125 patients who were on the medication.

It showed that both results from clinical research trials and real world practice were at least comparable and gave us clinicians confident when using it to treat our patients.

UPDATE (15/4/2018)

Screen Shot 2018-07-02 at 1.20.24 AM.png
Real world data from Samsung Medical Centre (2017): First-line afatinib use in advanced lung adenocarcinoma with positive EGFR mutation driver.
  • Average/ median progression free survival (PFS) for total 165 patients was around 19 months.
  • EGFR mutation Del 19 vs EGFR mutation L858R (average/ median PFS): 19.1 vs 15.1 months (works better for mutation Del 19).
  • Overall survival rate at 12 & 24 months: 91.0% & 70.7%, respectively.

The full paper above is interesting and I suggest those who is interested to read more about it.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s